43 research outputs found
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Background: The balance between T helper cells Th2- and Th1-related cytokines plays a key role in multiple
sclerosis (MS). A shift from a Th1 towards a Th2 cytokine profile could have a beneficial effect on the clinical course
of the disease. The objective of this study was to assess Th2/Th1 cytokine profile in relapsing-remitting MS (RRMS)
patients receiving an immunosuppressive treatment with natalizumab (NAT), or an immunomodulatory treatment
with glatiramer acetate (GA) after one year of treatment.
Methods: This was an observational cross-sectional study. All consecutive patients diagnosed with RRMS who had
received GA or NAT for 12 months were included in the study. We determined serum levels of Th1 and Th2
cytokines (interleukin [IL]-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-13, monocyte chemotactic protein
[MCP]-1, tumor-necrosis factor [TNF]-α, interferon [IFN]-γ and granulocyte macrophage colony stimulating factor
[GM-CSF]) by flow cytometry. Th2/Th1 bias was defined based on the ratio of IL-4, IL-5, IL-6 or IL-10 Th2 cytokines
and proinflammatory INF-γ or TNF-α Th1 cytokines.
Results: Eleven patients under treatment with NAT and 12 patients treated with GA were evaluated. RRMS patients
treated with NAT showed significantly higher levels of IL-6 (p < 0.05), MCP-1 (p < 0.01), and GM-CSF (p < 0.05)
compared to GA patients after one year of treatment. A trend for increasing of IL-12p70, IL-1b, TNF- α and IFN- γ
levels was also found in patients receiving NAT compared to GA patients. IL-4/IFN-γ, IFN-γ/TNF-α and IL-10/IFN-γ
ratios as markers of Th2/Th1 ratio were significantly elevated in GA patients compared to those receiving NAT
(p < 0.05).
Conclusion: In conclusion, our findings suggest that GA promotes a superior Th2-biased anti-inflammatory
response as compared with NAT in the systemic circulation of RRMS patients. Future studies with larger cohorts will
determine whether this immune Th2 shift in GA patients is associated with a beneficial effect on disease outcom
Adipose tissue-derived mesenchymal stem cells as a strategy to improve recovery after stroke
Introduction: Based on the positive results observed in experimental animal models, adipose
tissue-derived mesenchymal stem cells (AD-MSCs) constitute a promising therapy for stroke
treatment. However, several aspects need to be clarified to identify the optimal conditions for
successful clinical translation.
Areas covered: This review focuses on AD-MSC treatment for ischemic and hemorrhagic stroke
in experimental animal models. In addition, we will explore the optimization of treatment
conditions including AD-MSC production, administration routes and therapeutic windows for
their appropriate use in patients, and we will provide an update on clinical trials on this
therapy.
Expert opinion: Compared with other cell types, AD-MSCs have been less investigated in
stroke studies. Currently, experimental animal models have shown safety and efficacy with this
treatment after stroke. Due to several advantages of AD-MSCs, such as their abundance and
accessibility, they can be considered a promising strategy for use in patients. However, many
questions are still to be resolved regarding their mechanisms of action, immune system
modulation and the effects of AD-MSCs on all components of the brain that may be affected
after ischemic and hemorrhagic strokesThis project is supported by research grants PS12/01754 (Spanish Ministry of Science) and
INVICTUS (RD12/0014/0006) (Spanish Neurovascular Network), and Research Institute Carlos
III, Ministry Science and Innovatio
Effects of intravenous administration of allogenic bone marrow- and adipose tissue-derived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke
The electronic version of this article is the complete one and can be found online at: http://stemcellres.com/content/4/1/11Introduction: Stem cell therapy can promote good recovery from stroke. Several studies have demonstrated that
mesenchymal stem cells (MSC) are safe and effective. However, more information regarding appropriate cell type is
needed from animal model. This study was targeted at analyzing the effects in ischemic stroke of acute
intravenous (i.v.) administration of allogenic bone marrow- (BM-MSC) and adipose-derived-stem cells (AD-MSC) on
functional evaluation results and brain repair markers.
Methods: Allogenic MSC (2 × 106 cells) were administered intravenously 30 minutes after permanent middle
cerebral artery occlusion (pMCAO) to rats. Infarct volume and cell migration and implantation were analyzed by
magnetic resonance imaging (MRI) and immunohistochemistry. Function was evaluated by the Rogers and rotarod
tests, and cell proliferation and cell-death were also determined. Brain repair markers were analyzed by confocal
microscopy and confirmed by western blot.
Results: Compared to infarct group, function had significantly improved at 24 h and continued at 14 d after i.v.
administration of either BM-MSC or AD-MSC. No reduction in infarct volume or any migration/implantation of cells
into the damaged brain were observed. Nevertheless, cell death was reduced and cellular proliferation significantly
increased in both treatment groups with respect to the infarct group. At 14 d after MSC administration vascular
endothelial growth factor (VEGF), synaptophysin (SYP), oligodendrocyte (Olig-2) and neurofilament (NF) levels were
significantly increased while those of glial fiibrillary acid protein (GFAP) were decreased.
Conclusions: i.v. administration of allogenic MSC - whether BM-MSC or AD-MSC, in pMCAO infarct was associated
with good functional recovery, and reductions in cell death as well as increases in cellular proliferation,
neurogenesis, oligodendrogenesis, synaptogenesis and angiogenesis markers at 14 days post-infarctThis study was supported by grants from Cellerix, FIS 060575 and PS09/
01606 (Spanish Ministry of Science), CIDEM (Center for Innovation and
Business Development) and by RENEVAS (RD07/0026/2003) (Spanish
Neurovascular Network), the Carlos III Research Institute and the Ministry of Science and Innovatio
Plasma Amyloid-β dynamics in late-life major depression: a longitudinal study
Depressed individuals are twice as likely to develop Alzheimer’s disease (AD) as compared to controls. Brain amyloid-β (Aβ) deposition is believed to have a major role in AD pathogenesis but studies also suggest associations of Aβ dynamics and depression. The aim of this study was to test if plasma Aβ levels are longitudinally associated to late-life depression. We measured plasma levels of amyloid-β1-40 (Aβ40) and amyloid-β1-42 (Aβ42) peptides longitudinally for three consecutive years in 48 cognitively intact elderly subjects with late-life major depressive disorder (LLMD) and 45 age-matched cognitively healthy controls. We found that the Aβ42/Aβ40 plasma ratio was significantly and steadily lower in depressed subjects compared to controls (p < 0.001). At screening, Aβ42/Aβ40 plasma did not correlate with depression severity (as measured with Hamilton Depression Scale) or cognitive performance (as measured with Mini-Mental State Examination) but was associated to depression severity at 3 years after adjustment for age, education, cognitive performance, and antidepressants use. This study showed that reduced plasma Aβ42/Aβ40 ratio is consistently associated with LLMD diagnosis and that increased severity of depression at baseline predicted low Aβ42/Aβ40 ratio at 3 years. Future studies are needed to confirm these findings and examine if the consistently lower plasma Aβ42/Aβ40 ratio in LLMD reflects increased brain amyloid deposition, as observed in AD subjects, and an increased risk for progressive cognitive decline and AD
Comparison between xenogeneic and allogeneic adipose mesenchymal stem cells in the treatment of acute cerebral infarct: Proof of concept in rats
Background: Rat adipose tissue-derived-mesenchymal stem cells (rAD-MSCs) have proven to be safe in experimental
animal models of stroke. However, in order to use human AD-MSCs (hAD-MSCs) as a treatment for stroke patients, a
proof of concept is needed. We analyzed whether the xenogeneic hAD-MSCs were as safe and effective as allogeneic
rAD-MSCs in permanent Middle Cerebral Artery Occlusion (pMCAO) in rats.
Methods: Sprague–Dawley rats were randomly divided into three groups, which were intravenously injected with
xenogeneic hAD-MSCs (2 × 106), allogeneic rAD-MSCs (2 × 106) or saline (control) at 30 min after pMCAO. Behavior, cell
implantation, lesion size and cell death were evaluated. Brain markers such as GFAP (glial fibrillary acid protein), VEGF
(vascular endothelial growth factor) and SYP (synaptophysin) and tumor formation were analyzed.
Results: Compared to controls, recovery was significantly better at 24 h and continued to be so at 14 d after IV
administration of either hAD-MSCs or rAD-MSCs. No reduction in lesion size or migration/implantation of cells in the
damaged brain were observed in the treatment groups. Nevertheless, cell death was significantly reduced with respect
to the control group in both treatment groups. VEGF and SYP levels were significantly higher, while those of GFAP
were lower in the treated groups. At three months, there was no tumor formation.
Conclusions: hAD-MSCs and rAD-MSCs were safe and without side effects or tumor formation. Both treatment groups
showed equal efficacy in terms of functional recovery and decreased ischemic brain damage (cell death and glial scarring)
and resulted in higher angiogenesis and synaptogenesis marker levelsThis research was supported by research grants FIS06/0575, FIS09/01606,
FIS12/01754 and INVICTUS (RD12/0014/0006) (Spanish Neurovascular
Network), Cellerix, and Research Institute Carlos III, Ministry of Science and
Innovation of Spain
Brain-derived neurotrophic factor administration mediated oligodendrocyte differentiation and myelin formation in subcortical ischemic stroke
BACKGROUND AND PURPOSE:
Translational research is beginning to reveal the importance of trophic factors as a therapy for cellular brain repair. The purpose of this study was to analyze whether brain-derived neurotrophic factor (BDNF) administration could mediate oligodendrogenesis and remyelination after white matter injury in subcortical stroke.
METHODS:
Ischemia was induced in rats by injection of endothelin-1. At 24 hours, 0.4 μg/kg of BDNF or saline was intravenously administered to the treatment and control groups, respectively. Functional evaluation, MRI, and fiber tract integrity on tractography images were analyzed. Proliferation (KI-67) and white matter repair markers (A2B5, 2',3'-cyclic-nucleotide 3'-phosphodiesterase [CNPase], adenomatous polyposis coli [APC], platelet-derived growth factor receptor alpha [PDGFR-α], oligodendrocyte marker O4 [O4], oligodendrocyte transcription factor [Olig-2], and myelin basic protein [MBP]) were analyzed at 7 and 28 days.
RESULTS:
The BDNF-treated animals showed less functional deficit at 28 days after treatment than the controls (P<0.05). Although T2-MRI did not show differences in lesion size at 7 and 28 days between groups, diffusion tensor imaging tractography analysis revealed significantly better tract connectivity at 28 days in the BDNF group than in the controls (P<0.05). Increased proliferation of oligodendrocyte progenitors was observed in treated animals at 7 days (P<0.05). Finally, the levels of white matter repair markers (A2B5, CNPase, and O4 at 7 days; Olig-2 and MBP at 28 days) were higher in the BDNF group than in the controls (P<0.05).
CONCLUSIONS:
BDNF administration exerted better functional outcome, oligodendrogenesis, remyelination, and fiber connectivity than controls in rats subjected to subcortical damage in ischemic strokeSupported by research grants PS12/01754 (P.I.: EDT), INVICTUS Spanish
Neurovascular Network RD12/0014/0006 (BRF and JRC) and Sara Borrell postdoctoral fellowship CD12/00706 (LOO) from the Research Institute Carlos III, Ministry of
Science and Innovation of Spai
White matter injury restoration after stem cell administration in subcortical ischemic stroke
Introduction: Despite its high incidence, nerve fiber (axon and myelin) damage after cerebral infarct has not yet
been extensively investigated. The aim of this study was to investigate white matter repair after adipose-derived
mesenchymal stem cell (ADMSC) administration in an experimental model of subcortical stroke. Furthermore, we
aimed to analyze the ADMSC secretome and whether this could be implicated in this repair function.
Methods: An animal model of subcortical ischemic stroke with white matter affectation was induced in rats by
injection of endothelin-1. At 24 hours, 2 × 106 ADMSC were administered intravenously to the treatment group.
Functional evaluation, lesion size, fiber tract integrity, cell death, proliferation, white matter repair markers (Olig-2,
NF, and MBP) and NogoA were all studied after sacrifice (7 days and 28 days). ADMSC migration and implantation
in the brain as well as proteomics analysis and functions of the secretome were also analyzed.
Results: Neither ADMSC migration nor implantation to the brain was observed after ADMSC administration. In
contrast, ADMSC implantation was detected in peripheral organs. The treatment group showed a smaller functional
deficit, smaller lesion area, less cell death, more oligodendrocyte proliferation, more white matter connectivity and
higher amounts of myelin formation. The treated animals also showed higher levels of white matter-associated
markers in the injured area than the control group. Proteomics analysis of the ADMSC secretome identified 2,416
proteins, not all of them previously described to be involved in brain plasticity.
Conclusions: White matter integrity in subcortical stroke is in part restored by ADMSC treatment; this is mediated
by repair molecular factors implicated in axonal sprouting, remyelination and oligodendrogenesis. These findings
are associated with improved functional recovery after strokeThis study was supported by research grants PS12/01754, PI11/00909 and
INVICTUS (RD12/0014) (Spanish Neurovascular Network), SAF2010-37926,
ProteoRed-PT13/0001/0017 and a Sara Borrell postdoctoral fellowship
(CD12/00706, to LOO) from Research Institute Carlos III, Ministry of Science
and Innovation of Spain. We greatly appreciate advice from Prof. Avendaño
and Dr Negredo and we thank ServingMed.com for linguistic assistance.
Furthermore, TS (CP12/03121) and FC (CP14/00154) are recipients of a
research contract from Miguel Servet Program of Instituto de Salud Carlos II
Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
Natalizumab is a widely accepted drug for the relapsing–remitting subtype of multiple sclerosis (RRMS). The present longitudinal exploratory study in RRMS patients analyzes the effects of natalizumab treatment on the levels of pro-inflammatory and anti-inflammatory cytokine protein levels and also the frequency and suppressor function of regulatory T cells. Flow cytometry was used to determine cytokines and regulatory T cell frequency while regulatory T cell suppressor function was assayed in vitro at different time-points after starting with natalizumab. Results showed serum levels of pro-inflammatory interferon gamma and interleukin (IL)-12p70, as well as anti-inflammatory IL-4 and IL-10, were elevated just a few hours or days after first IV infusion of natalizumab. Interestingly, other cytokines like IL-5 or IL-13 were also elevated while pro-inflammatory IL-17, IL-2, and IL-1β increased only after a long-term treatment, suggesting different immune mechanisms. In contrast, we did not observe any effect of natalizumab treatment on regulatory T cell frequency or activity. In conclusion, these results suggest natalizumab has other immunological effects beyond VLA-4 interaction and inhibition of CNS extravasation, the relevance of which is as yet unknown and warrants further investigation
Recommended from our members
Using fMRI connectivity to define a treatment-resistant form of post-traumatic stress disorder.
A mechanistic understanding of the pathology of psychiatric disorders has been hampered by extensive heterogeneity in biology, symptoms, and behavior within diagnostic categories that are defined subjectively. We investigated whether leveraging individual differences in information-processing impairments in patients with post-traumatic stress disorder (PTSD) could reveal phenotypes within the disorder. We found that a subgroup of patients with PTSD from two independent cohorts displayed both aberrant functional connectivity within the ventral attention network (VAN) as revealed by functional magnetic resonance imaging (fMRI) neuroimaging and impaired verbal memory on a word list learning task. This combined phenotype was not associated with differences in symptoms or comorbidities, but nonetheless could be used to predict a poor response to psychotherapy, the best-validated treatment for PTSD. Using concurrent focal noninvasive transcranial magnetic stimulation and electroencephalography, we then identified alterations in neural signal flow in the VAN that were evoked by direct stimulation of that network. These alterations were associated with individual differences in functional fMRI connectivity within the VAN. Our findings define specific neurobiological mechanisms in a subgroup of patients with PTSD that could contribute to the poor response to psychotherapy.PEV was supported by the Medical Research Council (grant no. MR/K020706/1) and is a Fellow of MQ: Transforming Mental Health (MQF17_24)
Reparación de fibras de sustancia blanca tras infarto cerebral subcortical. Efecto de la administración del factor neurotrófico derivado de cerebro y de células troncales
Tesis doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Medicina. Fecha de lectura: 20-10-2015Este trabajo ha sido financiado con subvenciones concedidas por el Fondo de
Investigación Sanitaria (FIS): PS09/01606, PS12/01754 y las redes RETICSRD07/0026/2003
(RENEVAS) y RETICS-RD12/0014/0006 (INVICTUS) del
Instituto de Salud Carlos II